16 April,2023 08:25 AM IST | New York | Agencies
Girish Kirimanjeswara
A T-cell based COVID vaccine may last longer than the current jabs, providing long-lasting immunity against future emerging variants and could be used as a model for other seasonal viral diseases like the flu, an Indian-American researcher has revealed.
Focusing on the T-cell instead, Pennsylvania State University researchers in the US partnered with Evaxion Biotech on a study that was the first to demonstrate the effectiveness of an AI-generated vaccine in a live viral challenge model.
In their study, the researchers challenged mice with a lethal dose of SARS-CoV-2 and found that 87.5 per cent of the mice that were vaccinated with the T-cell-based vaccine survived, while only one of the control-group mice survived.
Additionally, all the vaccinated mice that survived cleared the infection within 14 days post-challenge, said the study published in the journal Frontiers in Immunology.
ALSO READ
Conor McGregor must pay $250K to woman who says he raped her, civil jury rules
US charges Indian national with conspiring to illegally export aviation components to Russia
NATO, Ukraine to hold emergency talks after Russia's attack with new hypersonic missile
Matt Gaetz says he won't return to Congress next year after withdrawing name for attorney general
Prominent figure from Canada's trucker protests against COVID-19 restrictions found guilty
"To our knowledge, this study is the first to show in vivo protection against severe COVID-19 by an AI-designed T-cell vaccine," said Girish Kirimanjeswara, associate professor of veterinary and biomedical sciences, Penn State.
"Our vaccine was extremely effective at preventing severe COVID-19 in mice, and it can be easily scaled up to start testing it in humans, as well," he added.
The research also paves the way for the potential rapid design of novel T-cell vaccines against emerging and seasonal viral diseases, like influenza.
"This means that vaccine manufacturers will have to keep creating new vaccines that target new variants, and people have to keep getting these new vaccines," he noted.
The virus would have to undergo too many mutations to be able to escape this T-cell-mediated immunity, so that is one advantage.
"The second advantage is that T-cell-mediated immunity is usually long lasting, so you don't need repeated booster doses," Kirimanjeswara explained.
This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever
